See more : International Silver, Inc. (ISLV) Income Statement Analysis – Financial Results
Complete financial analysis of Scilex Holding Company (SCLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scilex Holding Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Hanstone Gold Corp. (HANCF) Income Statement Analysis – Financial Results
- GenMont Biotech Incorporation (3164.TW) Income Statement Analysis – Financial Results
- Apple Inc. (AAPL) Income Statement Analysis – Financial Results
- Carnaby Resources Limited (CNB.AX) Income Statement Analysis – Financial Results
- African Energy Metals Inc. (NDENF) Income Statement Analysis – Financial Results
Scilex Holding Company (SCLX)
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 46.74M | 38.03M | 31.32M | 23.56M | 21.03M |
| Cost of Revenue | 15.68M | 10.80M | 3.63M | 2.15M | 5.80M |
| Gross Profit | 31.06M | 27.24M | 27.68M | 21.41M | 15.23M |
| Gross Profit Ratio | 66.45% | 71.61% | 88.40% | 90.88% | 72.41% |
| Research & Development | 12.75M | 9.05M | 9.20M | 9.96M | 85.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 119.64M | 64.90M | 50.58M | 42.97M | 64.70M |
| Other Expenses | 4.11M | 3.92M | 3.74M | 3.74M | 3.71M |
| Operating Expenses | 136.49M | 77.87M | 63.52M | 56.67M | 153.93M |
| Cost & Expenses | 152.17M | 88.67M | 67.16M | 58.82M | 159.73M |
| Interest Income | 0.00 | 9.60M | 11.76M | 13.12M | 460.00K |
| Interest Expense | 1.07M | 9.60M | 39.76M | 13.12M | 16.89M |
| Depreciation & Amortization | 4.15M | 4.45M | 4.15M | 3.78M | 3.75M |
| EBITDA | -109.10M | -9.30M | -44.88M | -31.48M | -134.49M |
| EBITDA Ratio | -233.41% | -122.71% | -102.37% | -133.62% | -639.40% |
| Operating Income | -105.43M | -50.63M | -35.84M | -35.26M | -138.70M |
| Operating Income Ratio | -225.55% | -133.13% | -114.44% | -149.65% | -659.42% |
| Total Other Income/Expenses | -8.89M | 27.27M | -52.58M | -12.31M | -39.90M |
| Income Before Tax | -114.32M | -23.36M | -88.42M | -47.57M | -178.59M |
| Income Before Tax Ratio | -244.57% | -61.42% | -282.34% | -201.92% | -849.10% |
| Income Tax Expense | 13.00K | 4.00K | 5.00K | -53.00K | 2.00K |
| Net Income | -114.33M | -23.36M | -88.42M | -47.52M | -178.59M |
| Net Income Ratio | -244.59% | -61.43% | -282.35% | -201.69% | -849.11% |
| EPS | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| EPS Diluted | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
| Weighted Avg Shares Out | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
| Weighted Avg Shares Out (Dil) | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024
PALO ALTO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label
PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain
PALO ALTO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa
PALO ALTO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report
PALO ALTO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the...
Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
PALO ALTO, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...
Source: https://incomestatements.info
Category: Stock Reports